Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
145
resultados
Última actualización
20/12/2024 [10:19:00]
Resumen de: US2024415940A1
Disclosed is a hyaluronidase peptide for use in the treatment or prophylaxis of a neurodegenerative disease and/or a dysfunctional blood-brain barrier associated with an increased cerebral glycosaminoglycan level, wherein the neurodegenerative disease is selected from Alzheimer's disease, vascular dementia, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), cerebral insult, brain trauma, cerebral inflammations, and autoimmune encephalitis, a pharmaceutical composition for use in the treatment or prophylaxis of the neurodegenerative disease, and a method of treating subjects exhibiting the respective neurodegenerative diseases and/or dysfunctional blood-brain barrier.
Resumen de: AU2023269025A1
Disclosed are therapeutic methods for reducing the rate of functionality loss in patients suffering from amyotrophic lateral sclerosis (ALS) during the accelerated stages of this disease.
Resumen de: AU2023283386A1
Compound of Formula (I)-(V), compositions comprising at least one compound chosen from compounds of Formula (I)-(V), and methods of using the same, including in treatment of Alzheimer's disease.
Resumen de: US2024417406A1
The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary diseases, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula I, the formula II or the formula III, or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the DESCRIPTION.
Resumen de: US2024417451A1
Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta/TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg/kg to 7.2 mg/kg once every four weeks.
Resumen de: US2024415846A1
The present invention relates to the treatment of an ALS patient with fausdil at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: US2024415871A1
Methods for the prevention or treatment of Alzheimer's disease in a human patient are disclosed comprising administering a hydroxypropyl-beta-cyclodextrin.
Resumen de: US2024415815A1
The present disclosure relates to an ionic liquid (IL)-based formulation comprising inhibitors of NADPH oxidases enzymes (Nox's), preferably isoforms 1 and 4, in particular the specific inhibitor 3-cyclohexyl-5-(2,4-dihydroxybenzylidene)-1-methyl-2-thiohydantoin, for the treatment, therapy or prevention of neurological diseases, in particular Parkinson's diseases.
Resumen de: US2024417371A1
Disclosed are a cannabidiol derivative, and a preparation method therefor and the use thereof, and in particular the use thereof in the prevention and treatment of a nervous system disease (such as epilepsy and Parkinson's disease). The cannabidiol derivative is obtained by means of screening from a series of synthetic derivatives, and animal test results show that the compounds can effectively shorten the epileptic seizure duration of an experimental animal, improves the epileptic seizure symptoms of the experimental animal, reduces the balance beam score of the Parkinson's model animal, increases the dopamine level and the tyrosine hydroxylase (TH) cell positivity in the substantia nigra (SubN), can be used for drug development and research on various diseases such as epilepsy and Parkinson's disease, and has a better application value.
Resumen de: US2024390336A1
Provided herein are methods for preventing biomineralization in brain tissue or neuronal tissue in vivo or in vitro by inhibiting the deposition of hydroxyapatite therein. Also provided are methods for delaying the progression or onset of Alzheimer's disease in a subject and for preventing the development of Alzheimer's disease in a post-traumatic brain injury subject. Contacting the brain tissue or neuronal tissue with or administering to a subject the drugs Levamisole and/or Foscarnet and/or a bisphosphonate inhibits or decreases levels of alkaline phosphatase and calcium and counteracts alpha-glycerophosphate therein to inhibit the activation of spontaneous biomineralization within a brain tissue to decrease or prevent ectopic biomineralization.
Resumen de: WO2024253420A1
The present invention relates to a human antibody specifically binding to a human TREM2 protein, and use thereof. The human monoclonal antibody specifically binding to TREM2 has been discovered through biopanning using a human synthetic antibody phage display library, and the antigen binding ability and biological activity of the discovered antibody have been identified. The present invention has a high affinity for TREM2, and thus enables the development of an antibody-based diagnosis system capable of diagnosing TREM2 as a biomarker of various Alzheimer's dementia. In addition, since a conventional therapeutic agent for Alzheimer's disease is mostly a symptom reliever through the temporary regulation of neurotransmitters, it is considered that the development of antibodies targeting TREM2 can lead to the development of promising new drugs having substantial therapeutic effects.
Resumen de: WO2024251212A1
Described herein are isoindolinone compounds and pharmaceutical compositions comprising said compounds. Additionally are described methods for the treatment of neurological disorders such as Huntington's disease (HD).
Resumen de: AU2023280227A1
The present invention relates to crystalline fine particle forms of 6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl)propyl)thieno2,3-bpyridine-5-carboxamide potassium salt (PRX-3140) for particle delivery systems (PDS) with good bioavailability and stability (I) for the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In other aspects, the present invention relates to oral dosage forms, methods of synthesizing said crystalline fine particle form, the preparation of particle delivery systems (PDS), final dosage forms (FDF).
Resumen de: WO2024254542A1
Disclosed herein are methods of selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain based on the risk of an ARIA event or brain hemorrhage. Also disclosed herein are methods of treating subjects having or suspected of having AD comprising subcutaneously administering an anti-Aβ protofibril antibody.
Resumen de: US2024409570A1
Disclosed herein is a compound and its use for the prognosis or diagnosis of neurodegenerative diseases. The compound has the structure of formula (I),According to embodiments of the present disclosure, the neurodegenerative disease may be an Alzheimer's disease (AD), Parkinson disease (PD), Huntington's disease (HD), frontotemporal dementia (FTD), Friedreich's ataxia, age-related macular degeneration, or Creutzfeldt-Jakob disease.
Resumen de: US2024409509A1
The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
Resumen de: US2024408109A1
The present invention relates to a pharmaceutical composition for preventing and/or treating neurodegenerative diseases. On the one hand, the active ingredient C21 steroid saponin of the pharmaceutical composition can significantly reduce the generation of an amyloid β-protein in N2a-APP695 cells and increase the clearance of excess A3; and on the other hand, the active ingredient C21 steroid saponin of the pharmaceutical composition can promote the proliferation of neuron cells, and has a protective effect on the neuronal cytotoxicity induced by neurotransmitters such as glutamate caused by the excessive accumulation of A3, thereby comprehensively playing a role in the treatment of neurodegenerative diseases. Therefore, the pharmaceutical composition has good application prospects in the preparation of an A3 formation inhibitor and a neuroprotective agent, and in drugs for preventing or treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
Resumen de: WO2024253422A1
The present invention relates to a pharmaceutical composition for the prevention or treatment of periodontal disease, or atherosclerosis or Alzheimer's disease caused by periodontal disease. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of periodontal disease, or atherosclerosis or Alzheimer's disease caused by periodontal disease, the composition comprising a peptide with the amino acid sequence of SEQ ID NO: 1, which is effective in inhibiting osteoclast formation, suppressing the formation of Porphyromonas gingivalis colonies, and inhibiting gingipain expression, while being safe for the body and having fewer side effects, including adverse reactions.
Resumen de: WO2024251289A1
Relating to the technical field of biological medicine, particularly the use of a kinase domain M7CK of TRPM7 in the preparation of a drug for treating Alzheimer's disease. The over-expression of M7CK can relieve cognitive impairment of a mouse model with AD by increasing an MMP14 phosphorylation level, improving learning and memory ability, increasing synaptic density and density of a presynaptic vesicle protein synaptophysin and a postsynaptic density protein PSD-95, promoting degradation of Aβ in soluble and insoluble components, and reducing accumulation of Aβ amyloid plaques. Therefore, the kinase domain of TRPM7 provided has a great application prospect in gene therapy of a patient with Alzheimer's disease
Resumen de: WO2024248510A1
The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Resumen de: WO2024248574A1
The present invention relates to a pharmaceutical composition which, by comprising sustained-release microspheres which consist of cagrilintide or a pharmaceutically acceptable salt thereof, an initial-burst inhibitor, and a biodegradable polymer, does not undergo rapid initial burst of a drug, has a high content of the drug relative to the particle size, and has high bioavailability, thus being able to minimize the patient's pain and inflammatory response that may occur when administered to the human body, and thus is effective in the prevention or treatment of diabetes, beta-cell dysfunction, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, and Alzheimer's disease.
Resumen de: WO2024246857A1
Disclosed are compounds of the following structure (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions of the compounds or salts, and their use for treating asthma or Parkinson's disease.
Resumen de: US2024398899A1
The present invention relates to the lectin protein for the treatment and prevention of neurodegenerative diseases. The invention further relates to the recombinant lectin protein is derived from Sclerotium rolfsii lectin having sequence 60% homologous to SEQ ID NO: 4 for the treatment and prevention of Neurodegenerative diseases. The invention specifically relates to lectin protein and its variants is derived from Sclerotium rolfsii lectin having sequence 60% homologous to SEQ ID NO: 4 for the treatment of prevention of Parkinson's disease, Alzheimer's disease, Dementia and symptoms of dementia.
Resumen de: US2024398792A1
The present invention generally relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogues and mimetics thereof, for treating, relieving, or alleviating Alsheimer's Disease, early onset Alzheimer's Disease, Alzheimer's Disease psychosis, or a combination thereof.
Nº publicación: US2024398822A1 05/12/2024
Solicitante:
PHARMATROPHIX INC [US]
Pharmatrophix, Inc
Resumen de: US2024398822A1
The disclosure provides compounds, salts and methods of use thereof for the prevention, treatment, delay of onset and management of Alzheimer's disease.
BOPI
Sede Electrónica
